Neurotrophic Keratitis – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
Neurotrophic keratitis is a degenerative corneal disease caused by trigeminal nerve (cranial nerve V) damage, resulting in corneal sensation loss and breakdown of the corneal epithelium. Corneal healing is also hampered in NK, so superficial corneal damage may progress to an actual epithelial defect, followed by corneal ulceration, stromal melting, and perforation. NK treatment aims to restore corneal integrity and prevent the disease from progressing. The cornea, lacrimal glands, conjunctiva, and eyelids are innervated by sensory branches of the ophthalmic division of the trigeminal nerve. The corneal epithelial cells mutually support the corneal nerves by releasing neurotrophic factors that promote neuronal extension and survival. The corneal nerves initiate two protective reflexes, blinking and tear secretion, responding to adverse stimuli. The nerves also support ocular surface health by releasing a host of trophic neuromediators, including substance P and calcitonin gene-related peptides that have been shown to promote corneal epithelial cell proliferation, differentiation, migration, and adhesion.
The
prevalence of Neurotrophic keratitis ranges from 56 to 67 cases per 100,000
population in the USA.
The competitive
landscape of Neurotrophic Keratitis includes country-specific approved and
pipeline therapies. Any asset/product-specific designation or review and
Accelerated Approval are tracked and supplemented with analyst commentary.
KOLs insights of Neurotrophic
Keratitis across 8 MM market from the center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Neurotrophic
Keratitis Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 Udonitrectag Syneos
Health Phase 2
2 rhNGF Dompé
Farmaceutici S.p.A Phase 2
3 OC-01 Oyster Point
Pharma, Inc. Phase 2
Comments
Post a Comment